Market Overview

Alcobra Ltd. to Release Fourth Quarter 2013 Results and Host Investor Conference Call on Thursday, February 13, 2014

Share:

TEL AVIV, Israel, Jan. 29, 2014 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq: ADHD), an emerging biopharmaceutical company primarily focused on the development and commercialization of its proprietary drug candidate, MG01CI (Metadoxine extended-release), to treat cognitive dysfunctions, such as ADHD and Fragile X Syndrome, today announced that it will report its financial results for the fourth quarter of 2013 and will host a corporate update conference call on Thursday, February 13, 2014.

Conference Call & Webcast  
Thursday, February 13, 2014 @ 8:30am Eastern Time/5:30am Pacific Time
Domestic: 855-469-0611
International: 484-756-4341
Passcode: 34670631
Webcast: www.alcobra-pharma.com
   
Replays  
Domestic:  855-859-2056
International:  404-537-3406
Passcode:  34670631

About Alcobra Ltd.

Alcobra Ltd. is an emerging biopharmaceutical company primarily focused on the development and commercialization of a proprietary drug candidate, MG01CI, to treat cognitive dysfunctions including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome.  MG01CI has completed Phase II studies to treat Attention Deficit Hyperactivity Disorder. The company was founded in 2008 and is headquartered in Tel Aviv, Israel. For more information please visit the Company's website, www.alcobra-pharma.com, the content of which is not incorporated herein by reference.

CONTACT: U.S. Investor Contacts: LifeSci Advisors, LLC Michael Rice 646-597-6979 mrice@lifesciadvisors.com Israel Investor Contact: Alcobra Investor Relations Debbie Kaye +972-72 2204661 debbie@alcobra-pharma.com
View Comments and Join the Discussion!